课题基金 / 基金详情

Specific active immunotherapy with anti-idiotype monoclonal antibody in lung cancer patients

Specific active immunotherapy with anti-idiotype monoclonal antibody in lung cancer patients
抗独特型单克隆抗体特异性主动免疫治疗肺癌患者
批准号:
05454381
负责人:
FUJISAWA Takehiko
金额:
$4.35万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (B)
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1995

项目摘要

项目成果

FUJISAWA Takehiko的其他基金

相似基金

相关文献

中文摘要
翻译
内部图像抗独特型抗体有望增强体内抗癌效应机制。我们建立了产生抗独特型单克隆抗体的杂交瘤,抗人单克隆抗体(HuMoAb) 4G12,该单克隆抗体与肺鳞状细胞癌反应强烈。两个克隆与4G12 HuMoAb反应,但与3H12 IgM HuMoAb、人IgM、人血清或胎牛血清不反应。这两种Ab2抗体(IgG1 kappa)、2B12和2H1在PC10细胞上对放射性标记的4G12的反应性分别有91.5%和90.3%的抑制作用,表明2B12和2H1抗体属于Ab2 β型。在交叉抑制实验中,2H1或2H1与4G12的结合不受2H1或2B12的抑制。因此,2B12和2H1被认为识别抗原结合位点上不同的表位。针对2B12和2H1的抗血清对PC10细胞表现出特异性反应,证实2B12和2H1表达了4G12抗体识别的肺鳞状细胞癌的内部图像。
英文摘要
Internal image anti-idiotype antibodies are expected to enhance anti-cancer effector mechanisms in vivo. We established hybridomas producing anti-idiotype monoclonal antibodies against a human monoclonal antibody (HuMoAb) 4G12 that reacts strongly with lung squamous cell carcinomas. Two clones reacted with 4G12 HuMoAb, but not with 3H12 IgM HuMoAb, human IgM,human serum or fetal calf serum. These two Ab2 antibodies (IgG1 kappa), 2B12 and 2H1 demonstrated 91.5% and 90.3% inhibition in their reactivity with radiolabelled 4G12 on PC10 cells, indicating that 2B12 and 2H1 antibodies were of Ab2 beta type. In crisscross inhibition assay, the binding of 2B12 or 2H1 to 4G12 was not inhibited by 2H1 or 2B12. Thus 2B12 and 2H1 were thought to recognize the different epitopes on the antigen binding sites. Antisera against 2B12 and 2H1 demonstrated specific reactivity to PC10 cells, confirming that 2B12 and 2H1 express internal images of lung squamous cell carcinoma recognized by the 4G12 antibody.
期刊论文(52)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
藤澤武彦: "抗イディオタイプモノクローナル抗体による肺非小細胞癌の診断と治療に関する検討" 病理生理. 14. 195-160 (1995)
Takehiko Fujisawa:“使用抗独特型单克隆抗体诊断和治疗非小细胞肺癌的研究”病理生理学 14. 195-160 (1995)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
藤澤武彦,他: "肺癌の診断と治療の基本戦略-組織型病期の診断は治療、予後にどう関連するか" Medical Practice. 11. 820-827 (1994)
Takehiko Fujisawa 等人:“肺癌诊断和治疗的基本策略 - 组织学分期的诊断与治疗和预后有何关系”《医学实践》11. 820-827 (1994)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takehiko Fujisawa: "Diagnosis and treatment of non-small cell carcinomas using anti-idiotype monoclonal antibody" Biopathology. 14-2. 159-160 (1995)
Takehiko Fujisawa:“使用抗独特型单克隆抗体诊断和治疗非小细胞癌”生物病理学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 26 条
    Clinical application of NKT cell immune system for lung cancer
    • 批准号:
      15209045
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $32.12万
    • 财政年份:
      2003
    • 负责人:
      FUJISAWA Takehiko
    • 依托单位:
    A immunotherapy for primary non small cell lung cancer with Vα24 NKT cells
    • 批准号:
      11357012
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $24.63万
    • 财政年份:
      1999
    • 负责人:
      FUJISAWA Takehiko
    • 依托单位:
    Anti-idiotype monoclonal antibody in the diagnosis and trectment of non-small cell carcinoma of the long
    • 批准号:
      02454324
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $4.29万
    • 财政年份:
      1990
    • 负责人:
      FUJISAWA Takehiko
    • 依托单位:
    Correlation between concommitant immunity and postoperative recurrence in primary resected lung cancers
    • 批准号:
      61480293
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $4.16万
    • 财政年份:
      1986
    • 负责人:
      FUJISAWA Takehiko
    • 依托单位:
    海外基金